Endocrinology Today—May 19, 2026

This week’s Endocrinology update highlights regulatory approvals, obesity and diabetes clinical findings, AI-driven risk prediction, and emerging metabolic disease strategies.

In Today’s Newsletter

Dive deeper

💉 Sandoz wins EU approval for insulin biosimilars [1] [EU • 15 May 2026]

https://lesechos-comfi.lesechos.fr/press-release/sandoz-group-ag-etr-sandoz-confirms-european-commission-approval-for-biosimilars-bysumlog-insulin-lispro-and-dazparda-insulin-aspart-strengthening-position-in-diabetes-yU0l4dkOVov
Context: Sandoz said the European Commission granted marketing authorisation across the reference-medicine diabetes indications.
Key point: Bysumlog (insulin lispro) and Dazparda (insulin aspart) are prefilled-pen biosimilars developed by Gan & Lee Pharmaceuticals.
Implication: Introduces competition that may affect pricing and formulary access.

🧬 Rhythm reports setmelanotide data at ECE 2026 [2] [EU • 12 May 2026]

https://firstwordpharma.com/story/7423728
Context: Real-world France data and Phase 3 analyses linked setmelanotide with BMI, hunger, and cardiometabolic improvements.
Key point: Rhythm Pharmaceuticals presented six ECE 2026 posters, including acquired hypothalamic obesity and Bardet-Biedl syndrome analyses.
Implication: May influence prescriber choice and payer reviews pending full data.

🦶 Singapore builds diabetes amputation-risk AI [3] [Singapore • 15 May 2026]

https://www.healthcareitnews.com/news/asia/singapore-develops-diabetes-amputation-risk-ai-and-more-briefs
Context: The model aims to classify diabetes patients by lower-extremity amputation risk three to five years before ulcers or infections.
Key point: Singapore General Hospital, SingHealth, and MOHT developed LEA-Net using anonymised SingHealth patient-record data.
Implication: May expand screening, initiation, and follow-up at scale.

🧪 Thyroid hormone profiles linked to liver failure prognosis [4] [14 May 2026]

https://www.news-medical.net/news/20260514/Thyroid-hormone-profiles-provide-critical-prognostic-clues-for-patients-facing-liver-failure.aspx
Context: Low T3 and related thyroid profiles were described as complementary prognostic markers, not standalone treatment triggers.
Key point: A review examined thyroid hormone dysfunction, non-thyroidal illness syndrome, and acute-on-chronic liver failure.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

🧫 Genprex reports preclinical Type 2 diabetes gene therapy data [5] [US • 14 May 2026]

https://www.prnewswire.com/news-releases/genprex-collaborators-present-positive-preclinical-data-on-diabetes-gene-therapy-for-type-2-diabetes-at-the-2026-american-society-of-gene-and-cell-therapy-annual-meeting-302771907.html
Context: The preclinical study reported reversal of hyperglycemia and improved beta-cell function after pancreatic delivery.
Key point: Genprex collaborators presented AAV-Pdx1/MafA, also called GPX-002, data at ASGCT 2026 in Type 2 diabetic mouse models.
Implication: Signals pipeline investment and modality expansion.

🔁 PCOS renamed PMOS in global consensus [6] [Global • 12 May 2026]

https://www.prnewswire.com/news-releases/global-experts-establish-new-name-for-pcos-to-reflect-multisystem-disease-302768983.html
Context: Experts said PMOS better reflects endocrine, metabolic, reproductive, dermatological, and psychological features.
Key point: A global consensus study in The Lancet renamed polycystic ovary syndrome as Polyendocrine Metabolic Ovarian Syndrome.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

🏥 Lupin receives US FDA approval for famotidine injection [7] [US • 13 May 2026]

https://www.prnewswire.com/news-releases/lupin-receives-us-fda-approval-for-famotidine-injection-usp-302771378.html
Context: The US FDA approved Lupin’s ANDA for IV famotidine in hospitalized patients and short-term oral-therapy alternatives.
Key point: Lupin’s Famotidine Injection USP, 20 mg/2 mL, is bioequivalent to Pepcid Injection and will be manufactured in Nagpur, India.
Implication: Introduces competition that may affect pricing and formulary access.

📲 Glooko and mylife expand diabetes data partnership [8] [Sweden–Switzerland • 12 May 2026]

https://www.businesswire.com/news/home/20260512745029/en/Glooko-and-mylife-Diabetes-Care-Expand-Diabetes-Data-Management-Partnership
Context: The agreement supports connected data management for mylife Loop powered by CamAPS FX and care teams.
Key point: Glooko will serve as mylife Diabetes Care’s primary data management platform for mylife products.
Implication: Could streamline initiation and adherence via remote prescribing and logistics.

Why It Matters

Diabetes access and affordability remain active themes, with Sandoz adding two EU-approved rapid-acting insulin biosimilars.
Diabetes technology is moving upstream, from device data management to AI-enabled risk prediction before complications appear.
Rare obesity care is becoming more data-rich, with setmelanotide analyses spanning real-world outcomes, Phase 3 measures, and disease burden.
Endocrine terminology is shifting toward multisystem framing, as PCOS becomes PMOS in a global consensus process.
Earlier-stage modalities remain active, with Genprex positioning GPX-002 as a beta-cell-focused gene therapy concept.

📚 View the full Endocrinology archive on our research hub page

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🧰 See our full range of services. Discover how we can help you.

🎯 Catch up on the Top Endocrinology news from the past two weeks, curated by the LucidQuest team.

🎬 Watch on YouTube.

FAQ

What did Sandoz receive approval for in Europe?

Sandoz said the European Commission approved Bysumlog (insulin lispro) and Dazparda (insulin aspart), both biosimilar insulins for diabetes mellitus. [1]

What did Rhythm report for setmelanotide at ECE 2026?

Rhythm described real-world and Phase 3 analyses in acquired hypothalamic obesity, plus research on hyperphagia in Bardet-Biedl syndrome. The source reports BMI, hunger, and cardiometabolic findings. [2]

What is Singapore’s LEA-Net diabetes AI intended to do?

LEA-Net is intended to predict lower-extremity amputation risk in diabetes patients three to five years before foot ulcers and infections develop. [3]

What is Genprex’s GPX-002?

GPX-002 is Genprex’s Pdx1/MafA diabetes gene therapy candidate. Collaborators reported preclinical mouse-model data showing reversal of hyperglycemia and improved beta-cell function. [5]

Why was PCOS renamed PMOS?

Experts said Polyendocrine Metabolic Ovarian Syndrome better reflects the condition’s endocrine, metabolic, reproductive, dermatological, and psychological features. [6]

What does the Glooko and mylife agreement cover?

Glooko will serve as mylife Diabetes Care’s primary data management platform, including support for mylife Loop powered by CamAPS FX. [8]

Entities / Keywords

Sandoz, Bysumlog, insulin lispro, Dazparda, insulin aspart, Gan & Lee Pharmaceuticals, Humalog, NovoRapid, insulin biosimilars
Rhythm Pharmaceuticals, setmelanotide, IMCIVREE, acquired hypothalamic obesity, Bardet-Biedl syndrome, hyperphagia, TRANSCEND
Singapore General Hospital, SingHealth, Ministry of Health Office for Healthcare Transformation, LEA-Net, diabetes amputation risk AI
Thyroid hormones, T3, FT3, FT4, TSH, non-thyroidal illness syndrome, acute-on-chronic liver failure, MELD, CLIF-C
Genprex, GPX-002, Pdx1, MafA, AAV-8, Type 2 diabetes, beta-cell function, ASGCT 2026
PCOS, PMOS, Polyendocrine Metabolic Ovarian Syndrome, University of Colorado Anschutz, The Lancet
Lupin, Famotidine Injection USP, Pepcid Injection, ANDA, US FDA, GERD, Zollinger-Ellison Syndrome
Glooko, mylife Diabetes Care, mylife Loop, CamAPS FX, CamDiab, automated insulin delivery, diabetes data management